Tahoe Therapeutics today announced $30 million in new funding to build the definitive foundational dataset for training Virtual Cell Models. With this, the team will generate one billion single-cell datapoints, mapping one million drug-patient interactions, a scale previously impossible. The dataset will support the discovery of new precision medicines for cancer and beyond. Tahoe will also select a single partner to share the data and accelerate translation to clinical outcomes.
Tahoe Therapeutics (formerly Vevo Therapeutics) was co-founded by Hani Goodarzi, Kevan Shokat, and Johnny Yu.